Cannabinoid Signalling Group

The Cannabinoid Signalling Group belongs to the Department of Biochemistry and Molecular Biology at the Schools of Chemistry and Biology, Complutense University, Madrid, Spain. The group is coordinated by Manuel Guzmán. Nowadays, Ismael Galve-Roperh, Cristina Sánchez and Guillermo Velasco coordinate three of the ongoing research lines in our group.

Cannabinoid Signalling Group

 The major focus of our group is the study of the mechanisms by which cannabinoids – the active components of Cannabis sativa L. – and their endogenous counterparts control the proliferation, differentiation and survival of different types of cells.

These are our research lines:

Recent publications

i

Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (2019)

Blasco-Benito, S. et al.

Link to the article

For more publications from Breast Cancer, click here.

i

Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration (2019)

Aguareles, J. et al.

Link to the article

For more publications from Neurogenesis, click here.

i

Astroglial monoacylglycerol lipase controls mutant huntingtin-induced damage of striatal neurons (2019)

Ruiz-Calvo, A. et al.

Link to the article

For more publications from Neuroprotection, click here.

i

Targeting Glioma Initiating Cells With A Combined Therapy Of Cannabinoids And Temozolomide (2018)

López-Valero, I. et al.

Link to the article

For more publications from Brain Tumors, click here.

Acknowledgements

Our group acknowledges the support of funding institutions, both public (Ministerio de Economía y Competitividad, Instituto de Salud Carlos III – CIBERNED, Instituto Universitario de Investigación en Neuroquímica, Instituto de Investigación Sanitaria i+12, Instituto Ramón y Cajal de Investigación Sanitaria, Instituto de Investigación Sanitaria San Carlos) and private (GW Pharmaceuticals, VivaCell Biotechnology, Zelda Therapeutics).